The Future of Commercial Spray Drying: Supporting the Medicines of Tomorrow
Day 1 Manufacturing 5.0 Stage
06/10/2026 14:15 - 14:40pm
Contributors
Jason Bertola : Executive Director, Commercial Development for Drug Substance and Particle Engineering - Lonza
As poorly soluble molecules continue to represent a significant portion of pharmaceutical pipelines, demand for amorphous solid dispersions (ASDs) and spray-dried dispersions (SDDs) is increasing across the industry. At the same time, companies face growing challenges as programs transition from development to commercial manufacturing, where scalability, supply continuity, and access to specialised expertise become critical considerations.
Spray drying has emerged as a leading technology for enabling bioavailability enhancement and supporting the successful commercialisation of complex molecules. In this presentation, we will discuss market trends shaping demand for SDDs, common scale-up considerations, and strategies to support long-term commercial success. Drawing on extensive experience supporting development and commercial programs, the session will explore how an integrated approach can help pharmaceutical companies accelerate progression, reduce risk, and establish resilient manufacturing strategies for future growth.